<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515785</url>
  </required_header>
  <id_info>
    <org_study_id>INCB-DEMA-ALL-401</org_study_id>
    <nct_id>NCT03515785</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - &quot;POSEIDON&quot;</brief_title>
  <official_title>A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - &quot;POSEIDON&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Biosciences International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®)
      in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical
      practice in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Complete hematological remission (CR) rate</measure>
    <time_frame>6 months</time_frame>
    <description>CR defined as leukemic cells not detectable by light microscopy in bone marrow (BM), peripheral blood (PB), or cerebrospinal fluid (CSF) (BM &lt; 5% blasts).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>1, 3, 9, and 12 months</time_frame>
    <description>CR defined as leukemic cells not detectable by light microscopy in BM, PB, or CSF (BM &lt; 5% blasts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR rate</measure>
    <time_frame>1, 3, 6, 9, and 12 months</time_frame>
    <description>CR defined as leukemic cells not detectable by light microscopy in BM, PB, or CSF (BM &lt; 5% blasts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CR</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as time from enrollment to first CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease (MRD) level</measure>
    <time_frame>3, 6, 9, and 12 months</time_frame>
    <description>Minimal residual disease level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best MRD (MolR) level rate</measure>
    <time_frame>12 months</time_frame>
    <description>MolR defined as molecular/MRD response, less than MolCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to best MRD (MolR) level</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>MolR defined as molecular/MRD response, less than MolCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of molecular response</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by MRD log reduction (MolR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of best molecular response (MolCR)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>MolCR defined as complete molecular remission/MRD negativity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as the time to molecular relapse or hematological relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Defined as time from enrollment to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescribed dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Prescribed dose of Iclusig® in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily average dose</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The average daily dose of Iclusig® in milligrams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as an adverse event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events of special interest (AESI)</measure>
    <time_frame>12 months</time_frame>
    <description>AESI defined as vascular occlusive events, including arterial and venous events, as defined in the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of hospital days</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as overnight stay(s), each night in the hospital will be counted as 1 day.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>BCR-ABL Positive Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Ph+ ALL Patients</arm_group_label>
    <description>Patients with Ph+ ALL being treated with Iclusig®.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Ph+ ALL being treated with Iclusig® in Europe.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with BCR-ABL (Ph+) positive ALL who are initiating Iclusig®, or for
             whom Iclusig® was initiated after January 2015.

          -  Patients who have the ability to understand the requirements of the study and provide
             written informed consent to comply with the study data collection procedures.

        Exclusion Criteria:

          -  Patients previously treated with investigational ponatinib.

          -  Patients who are pregnant and/or breastfeeding.

          -  Concurrent treatment with another tyrosine kinase inhibitor for Ph+ALL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Hoelzer, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncologikum Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Plzeň</name>
      <address>
        <city>Plzeň</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ihbt/Úhkt</name>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80080</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69361</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Cancer Institute Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Halle/Saale</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>ponatinib</keyword>
  <keyword>tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

